



4CPS-034

REAL-WORLD STUDY OF TRIFLURIDINE/TIPIRACIL-BEVACIZUMAB IN METASTATIC COLORECTAL CANCER

F. Madriñán González, C. Otero Villalustre, E. Mateos Egido, A.C. Rodríguez Negrín, E. Gandullo Sánchez, G. Avanzini Martínez, V. García Navarro, C. Espín Martínez, I. Ruiz Santos, A.M. Álamo Medina, D. Fernández Vera.

Contact data: fmadgon@gobiernodecanarias.org

Complejo Hospitalario Universitario Insular Materno Infantil de Las Palmas de Gran Canaria

✓ Background and Importance

Due to the high incidence of metastatic colorectal cancer (mCRC) in our area, we aimed to investigate the efficacy and safety of trifluoridine/tipiracil (TAS)-bevacizumab.

✓ Aim and Objectives

Evaluate the efficacy and safety of TAS-bevacizumab in patients with mCRC.

✓ Material and Methods

Study Design: Observational, retrospective study.
Patients: Included from 01/01/2022 to 30/07/2024.
Variables: Age, sex, ECOG score, mutations, prior treatments, adverse events (AEs), and response type.

Data Sources: Electronic medical record DRAGO-AE®.
Efficacy Metrics: PFS and OS calculated using Kaplan-Meier.
Safety Metrics: AEs severity graded per CTCAE v4.0.
Statistical Analysis: Descriptive statistics using SPSS® Statistics22 software.

✓ Results

Patients: 42 (29 men, 13 women), median age 62.5 years (range 39-85).

➤ Characteristics:

- ECOG 0-1: 66.67%
- ECOG 2: 33.33%
- KRAS mutation: 50%
- BRAF mutation: 4.77%

➤ Treatment Response:

- Partial response: 2.38%
- Stable disease: 23.81%
- Disease progression: 54.76%
- No response: 19.05% (50% deceased, 50% <3 cycles).

➤ Treatment Lines:

- 2nd Line: 2.38%
- 3rd Line: 80.95%
- 4th Line: 16.67%

➤ End of Treatment Reasons:


- Disease progression: 88.6%
- Toxicity: 5.7%
- Discontinuation: 5.7%

Survival Metrics:

Median PFS: 4.05 months (95% CI: 3.38-4.71)

Median OS: 11.51 months (95% CI: 7.57-15.45)

Adverse Events Distribution



✓ Conclusion and Relevance

- PFS: Lower than the SUNLIGHT study (5.6 months) likely due to more ECOG=2 patients.
- OS: Longer than literature (10.8 months).
- Safety: AEs consistent with literature, though fewer grade 3-4 events.